
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/798471/publications.pdf Version: 2024-02-01



TORIAS SIÃORIOM

#	Article	IF	CITATIONS
1	The Consensus Coding Sequences of Human Breast and Colorectal Cancers. Science, 2006, 314, 268-274.	12.6	3,130
2	The Genomic Landscapes of Human Breast and Colorectal Cancers. Science, 2007, 318, 1108-1113.	12.6	3,049
3	A pathology atlas of the human cancer transcriptome. Science, 2017, 357, .	12.6	2,570
4	The colorectal microRNAome. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3687-3692.	7.1	890
5	PDGF receptors as cancer drug targets. Cancer Cell, 2003, 3, 439-443.	16.8	449
6	Inhibition of PDCF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Research, 2002, 62, 5476-84.	0.9	356
7	Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16224-16229.	7.1	285
8	The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Research, 1999, 59, 3719-23.	0.9	216
9	Prognostic Significance of Stromal Platelet-Derived Growth Factor Î ² -Receptor Expression in Human Breast Cancer. American Journal of Pathology, 2009, 175, 334-341.	3.8	215
10	Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Research, 2001, 61, 5778-83.	0.9	206
11	In Situ Detection of Phosphorylated Platelet-derived Growth Factor Receptor Î ² Using a Generalized Proximity Ligation Method. Molecular and Cellular Proteomics, 2007, 6, 1500-1509.	3.8	197
12	Sustained TGFÎ ² exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene, 2008, 27, 1218-1230.	5.9	193
13	Platelet-Derived Growth Factor Production by B16 Melanoma Cells Leads to Increased Pericyte Abundance in Tumors and an Associated Increase in Tumor Growth Rate. Cancer Research, 2004, 64, 2725-2733.	0.9	174
14	Multispectral imaging for quantitative and compartmentâ€specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients. Journal of Pathology, 2018, 244, 421-431.	4.5	159
15	STC1 Expression By Cancer-Associated Fibroblasts Drives Metastasis of Colorectal Cancer. Cancer Research, 2013, 73, 1287-1297.	0.9	144
16	Transgenic Overexpression of Platelet-Derived Growth Factor-C in the Mouse Heart Induces Cardiac Fibrosis, Hypertrophy, and Dilated Cardiomyopathy. American Journal of Pathology, 2003, 163, 673-682.	3.8	137
17	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood, 2016, 127, 1007-1016.	1.4	130
18	Preferential oxidation of the second phosphatase domain of receptor-like PTP-α revealed by an antibody against oxidized protein tyrosine phosphatases. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1886-1891.	7.1	121

#	Article	IF	CITATIONS
19	A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Research, 2007, 17, 1304-1318.	5.5	121
20	Targeted DNA sequencing and in situ mutation analysis using mobile phone microscopy. Nature Communications, 2017, 8, 13913.	12.8	118
21	Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15. Cancer Research, 2014, 74, 3408-3417.	0.9	101
22	Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosomes and Cancer, 2011, 50, 82-94.	2.8	79
23	Targeted resequencing of candidate genes using selector probes. Nucleic Acids Research, 2011, 39, e8-e8.	14.5	66
24	Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorganic and Medicinal Chemistry, 2003, 11, 2007-2018.	3.0	62
25	Somatic mutations in the notch, NFâ€KB, PIK3CA, and hedgehog pathways in human breast cancers. Genes Chromosomes and Cancer, 2012, 51, 480-489.	2.8	58
26	U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta OncolÃ ³ gica, 2018, 57, 187-194.	1.8	52
27	Oral Imatinib Mesylate (STI571/Gleevec) Improves the Efficacy of Local Intravascular Vascular Endothelial Growth Factor-C Gene Transfer in Reducing Neointimal Growth in Hypercholesterolemic Rabbits. Circulation, 2004, 109, 1140-1146.	1.6	47
28	Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Research, 2000, 60, 6723-9.	0.9	47
29	In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics. Oncotarget, 2013, 4, 2407-2418.	1.8	42
30	Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Scientific Reports, 2019, 9, 12184.	3.3	39
31	Characterization of the chronic myelomonocytic leukemia associated TEL-PDGFβR fusion protein. Oncogene, 1999, 18, 7055-7062.	5.9	36
32	Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing. BMC Genomics, 2013, 14, 165.	2.8	33
33	Molecular pathways in tumor progression: from discovery to functional understanding. Molecular BioSystems, 2009, 5, 902.	2.9	30
34	Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer. Cancer Research, 2017, 77, 1730-1740.	0.9	29
35	Loss of DIP2C in RKO cells stimulates changes in DNA methylation and epithelial-mesenchymal transition. BMC Cancer, 2017, 17, 487.	2.6	29
36	VEGF receptorâ€2/neuropilin 1 <i>trans</i> omplex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival. Journal of Pathology, 2018, 246, 311-322.	4.5	28

#	Article	IF	CITATIONS
37	Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy. Pharmaceuticals, 2021, 14, 57.	3.8	27
38	Transcriptional modulator ZBED6 affects cell cycle and growth of human colorectal cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7743-7748.	7.1	26
39	Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2016, 22, 6217-6227.	7.0	26
40	Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It?. Cancers, 2020, 12, 3308.	3.7	25
41	Tumor Vessel Up-Regulation of INSR Revealed by Single-Cell Expression Analysis of the Tyrosine Kinome and Phosphatome in Human Cancers. American Journal of Pathology, 2015, 185, 1600-1609.	3.8	24
42	Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. Breast Cancer Research and Treatment, 2019, 178, 459-467.	2.5	23
43	Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. Acta Oncológica, 2020, 59, 417-426.	1.8	22
44	Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression. Clinical Epigenetics, 2020, 12, 74.	4.1	22
45	Systematic analyses of the cancer genome: lessons learned from sequencing most of the annotated human protein-coding genes. Current Opinion in Oncology, 2008, 20, 66-71.	2.4	21
46	A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer. Cancers, 2021, 13, 16.	3.7	21
47	Automated serial extraction of DNA and RNA from biobanked tissue specimens. BMC Biotechnology, 2013, 13, 66.	3.3	18
48	Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort. Annals of Surgical Oncology, 2020, 27, 1036-1045.	1.5	18
49	Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine <i>N</i> â€Acetyltransferase NAT2. Angewandte Chemie - International Edition, 2020, 59, 14342-14346.	13.8	18
50	Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy. Nature Communications, 2020, 11, 1308.	12.8	18
51	Somatic Mutations in CCK2R Alter Receptor Activity that Promote Oncogenic Phenotypes. Molecular Cancer Research, 2012, 10, 739-749.	3.4	16
52	A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant <i>In Vitro</i> Multicompound Analyses. Molecular Cancer Therapeutics, 2014, 13, 1964-1976.	4.1	16
53	Completeness and accuracy of the registration of recurrences in the Swedish Colorectal Cancer Registry (SCRCR) and an update of recurrence risk in colon cancer. Acta Oncológica, 2021, 60, 842-849.	1.8	16
54	Profiling chromatin accessibility in formalin-fixed paraffin-embedded samples. Genome Research, 2022, 32, 150-161.	5.5	16

#	Article	IF	CITATIONS
55	Large-scale identification of novel transcripts in the human genome. Genome Research, 2007, 17, 287-292.	5.5	15
56	KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer. Frontiers in Oncology, 2022, 12, 826073.	2.8	15
57	The Immune Landscape of Colorectal Cancer. Cancers, 2021, 13, 5545.	3.7	14
58	88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer. Annals of Oncology, 2020, 31, S276.	1.2	13
59	Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer. Cancers, 2020, 12, 3238.	3.7	13
60	Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis. Journal of Experimental and Clinical Cancer Research, 2021, 40, 225.	8.6	13
61	Somatic <i>PRDM2</i> c.4467delA mutations in colorectal cancers control histone methylation and tumor growth. Oncotarget, 2017, 8, 98646-98659.	1.8	13
62	<i>In situ</i> sequencing identifies <i><scp>TMPRSS2–ERG</scp></i> fusion transcripts, somatic point mutations and gene expression levels in prostate cancers. Journal of Pathology, 2014, 234, 253-261.	4.5	12
63	Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity. Oncotarget, 2017, 8, 30217-30234.	1.8	12
64	Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer. Cancers, 2022, 14, 1757.	3.7	12
65	Scalable In Situ Hybridization on Tissue Arrays for Validation of Novel Cancer and Tissue-Specific Biomarkers. PLoS ONE, 2012, 7, e32927.	2.5	11
66	Structural Alterations from Multiple Displacement Amplification of a Human Genome Revealed by Mate-Pair Sequencing. PLoS ONE, 2011, 6, e22250.	2.5	11
67	A new distance measure for non-identical data with application to image classification. Pattern Recognition, 2017, 63, 384-396.	8.1	10
68	Determining the use of preoperative (chemo)radiotherapy in primary rectal cancer according to national and international guidelines. Radiotherapy and Oncology, 2019, 136, 106-112.	0.6	10
69	Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort. Scientific Reports, 2020, 10, 19304.	3.3	10
70	Neoadjuvant rectal (NAR) score: Value evaluating the efficacy of neoadjuvant therapy and prognostic significance after surgery?. Radiotherapy and Oncology, 2021, 157, 70-77.	0.6	10
71	FACT-seq: profiling histone modifications in formalin-fixed paraffin-embedded samples with low cell numbers. Nucleic Acids Research, 2021, 49, e125-e125.	14.5	10
72	Automated Genotyping of Biobank Samples by Multiplex Amplification of Insertion/Deletion Polymorphisms. PLoS ONE, 2012, 7, e52750.	2.5	9

#	Article	IF	CITATIONS
73	Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells. Genome Medicine, 2018, 10, 2.	8.2	6
74	Accurate population-based model for individual prediction of colon cancer recurrence. Acta Oncológica, 2021, 60, 1241-1249.	1.8	6
75	Computational and molecular tools for scalable rAAV-mediated genome editing. Nucleic Acids Research, 2015, 43, e30-e30.	14.5	5
76	Stage distribution utilizing magnetic resonance imaging in an unselected population of primary rectal cancers. European Journal of Surgical Oncology, 2018, 44, 1858-1864.	1.0	5
77	Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer. British Journal of Cancer, 2019, 121, 303-311.	6.4	5
78	Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer. Scientific Reports, 2020, 10, 22436.	3.3	5
79	Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine N â€Acetyltransferase NAT2. Angewandte Chemie, 2020, 132, 14448-14452.	2.0	2
80	Iron Chelator VLX600 Inhibits Mitochondrial Respiration and Promotes Sensitization of Neuroblastoma Cells in Nutrition-Restricted Conditions. Cancers, 2022, 14, 3225.	3.7	2
81	Identification of driver genes in microsatellite-unstable colorectal cancers. Colorectal Cancer, 2013, 2, 515-523.	0.8	0
82	Targeting tumor vulnerabilities associated with loss of heterozygosity. Molecular and Cellular Oncology, 2020, 7, 1759390.	0.7	0